CalciMedica, Inc.

CALC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-29.6M $-13.7M $-34.4M $-7.8M $-35.8M $-27.5M $-37.0M
Depreciation & Amortization $58.0K $52.0K
Depreciation $46.0K $58.0K $58.0K $52.0K $519.0K $395.0K $303.0K
Amortization
Stock-Based Compensation $3.0M $2.3M $12.0M $1.8M $5.4M $1.8M $738.0K
Net Cash from Operating Activities $-21.2M $-21.1M $-25.7M $-11.8M $-31.5M $-32.1M $-31.2M
Investing Activities
Capital Expenditures $28.0K $8.0K $78.0K $4.0K $488.0K $1.0M $605.0K
Business Acquisitions
Net Cash from Investing Activities $9.6M $-4.4M $8.9M $-4.0K $10.8M $-42.6M $-20.6M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $15.2M $28.0M $20.9M $8.5M $695.0K $92.2M $54.9M
Net Change in Cash $3.6M $2.4M $4.1M $-3.3M $-20.1M $17.5M $3.0M
Free Cash Flow $-21.2M $-21.2M $-25.8M $-11.8M $-32.0M $-33.1M $-31.8M